Spots Global Cancer Trial Database for myeloproliferative neoplasm (mpn)
Every month we try and update this database with for myeloproliferative neoplasm (mpn) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| Safety of Flunotinib Maleate Tablets for the Treatment of Patients With Myeloproliferative | NCT05153343 | Myeloproliferat... Myelofibrosis，M... | flonoltinib 25m... flonoltinib 50m... flonoltinib 100... flonoltinib 150... flonoltinib 225... flonoltinib 325... | 18 Years - | Chengdu Zenitar Biomedical Technology Co., Ltd | |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients | NCT04243122 | Myeloproliferat... Essential Throm... JAK2 Mutation Polycythemia Ve... Primary Myelofi... Venous Thromboe... | Apixaban 2.5 MG... Aspirin 81 mg | 18 Years - | Ottawa Hospital Research Institute | |
| Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors | NCT05115344 | Myeloproliferat... Myelofibrosis，M... | flonoltinib 25m... flonoltinib 50m... flonoltinib 100... flonoltinib 150... flonoltinib 225... flonoltinib 325... | 18 Years - | Guizhou Bailing Group Pharmaceutical Co Ltd | |
| Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors | NCT05115344 | Myeloproliferat... Myelofibrosis，M... | flonoltinib 25m... flonoltinib 50m... flonoltinib 100... flonoltinib 150... flonoltinib 225... flonoltinib 325... | 18 Years - | Guizhou Bailing Group Pharmaceutical Co Ltd | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients | NCT04243122 | Myeloproliferat... Essential Throm... JAK2 Mutation Polycythemia Ve... Primary Myelofi... Venous Thromboe... | Apixaban 2.5 MG... Aspirin 81 mg | 18 Years - | Ottawa Hospital Research Institute | |
| Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia | NCT00726232 | Myeloproliferat... | Ruxolitinib | 18 Years - | Incyte Corporation | |
| Safety of Flunotinib Maleate Tablets for the Treatment of Patients With Myeloproliferative | NCT05153343 | Myeloproliferat... Myelofibrosis，M... | flonoltinib 25m... flonoltinib 50m... flonoltinib 100... flonoltinib 150... flonoltinib 225... flonoltinib 325... | 18 Years - | Chengdu Zenitar Biomedical Technology Co., Ltd | |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients | NCT04243122 | Myeloproliferat... Essential Throm... JAK2 Mutation Polycythemia Ve... Primary Myelofi... Venous Thromboe... | Apixaban 2.5 MG... Aspirin 81 mg | 18 Years - | Ottawa Hospital Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
